Targeting RET Kinase in Neuroendocrine Prostate Cancer

The increased treatment of metastatic castration resistant prostate cancer (mCRPC) with second-generation anti-androgen therapies (ADT) has coincided with a greater incidence of lethal, aggressive variant prostate cancer (AVPC) tumors that have lost dependence on androgen receptor (AR) signaling. Th...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Mol Cancer Res
Main Authors: VanDeusen, Halena R., Ramroop, Johnny R., Morel, Katherine L., Bae, Song Yi, Sheahan, Anjali V., Sychev, Zoi, Lau, Nathan A., Cheng, Larry C., Tan, Victor M., Li, Zhen, Petersen, Ashley, Lee, John K., Park, Jung Wook, Yang, Rendong, Hwang, Justin H., Coleman, Ilsa, Witte, Owen N., Morrissey, Colm, Corey, Eva, Nelson, Peter S., Ellis, Leigh, Drake, Justin M.
Formato: Artigo
Idioma:Inglês
Publicado: 2020
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7415621/
https://ncbi.nlm.nih.gov/pubmed/32461304
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1541-7786.MCR-19-1245
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares